Grifols SA
(Other OTC/NBB : GIKLY)

( )
GIKLY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 4.08%35.210.9%$1169.31m
JNJJohnson & Johnson 2.07%145.320.7%$989.81m
BMYBristol-Myers Squibb Co. 0.58%57.761.0%$910.15m
MRKMerck & Co., Inc. 0.82%77.360.7%$748.50m
ABBVAbbVie, Inc. 1.08%97.881.9%$710.81m
LLYEli Lilly & Co. -0.73%162.171.1%$628.12m
AZNAstraZeneca Plc -0.97%53.241.2%$287.30m
RPRXRoyalty Pharma Plc -7.52%44.060.1%$183.39m
NVSNovartis AG -1.02%86.120.2%$139.48m
RGENRepligen Corp. -2.87%122.517.1%$110.64m
GSKGlaxoSmithKline Plc 0.40%40.070.2%$106.00m
NVONovo Nordisk A/S -0.46%65.140.1%$83.40m
RETAReata Pharmaceuticals, Inc. -0.89%153.033.4%$66.27m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -6.20%69.540.0%$62.33m
SNYSanofi 1.31%50.940.2%$61.16m

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.